BioPharma DiveOriginal article
Psychedelics developer Definium scores more positive data for LSD pill
Phase 3positiveLSD pillPositive
AI Analysis
Summary
Definium announced positive late-stage study results for its LSD pill in generalized anxiety disorder, which analysts characterized as a clean win with multibillion-dollar sales potential.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Late-stage study for generalized anxiety disorder described as a 'clean win' by analysts
Importance:7/10
Sentiment:
0.85
psychedelicsLSDgeneralized anxiety disorderlate-stagepositive data
Read the original article
Published by BioPharma Dive on August 12, 2026 2:33 PM